Two CD38-specific antibodies (daratumumab, isatuximab) have recently been licensed for the treatment of multiple myeloma, since these tumor cells often upregulate cell surface expression of CD38 to very high levels (van de Donk et al., 2017). Here, CD38 is linked to plasma cell myeloma.